Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Smart_Money who wrote (78925)	6/10/1999 1:57:00 PM
From: LadyNada	Read Replies (3) \| Respond to of 119973

KNSY fda news 01:38 PM PRN Kensey Nash Receives FDA Approval to Commence Clinical Trials for New Syste... More News... How Do I... Kensey Nash Receives FDA Approval to Commence Clinical Trials for New System To Treat Saphenous Vein Graft Disease Aegis Vortex(TM) System Will Be Clinically Evaluated at Five Centers June 10, 1999 01:38 PM EXTON, Pa., June 10 /PRNewswire/ -- Kensey Nash Corporation KNSY today announced that it has received conditional approval from the US Food and Drug administration (FDA) to commence clinical trials in the US for its Aegis Vortex(TM) System, a device designed to open diseased saphenous vein grafts in patients who previously have undergone coronary bypass surgery. A feasibility study of the device is planned at five centers in the US, concurrent with a separate study at several centers in Europe.